Objective:

To evaluate whether low-dose (5 mg) SGLT2 inhibitors provide comparable efficacy and safety compared with the standard 10 mg dose and to non-users in heart failure patients with diabetes.

Approach:

Key Findings:

• The 5 mg group showed a lower risk of the primary outcome compared to the 10 mg group (HR: 0.73, 95% CI: 0.66–0.81; P < 0.001).
• The 5 mg group also had a lower risk of all-cause death compared to the 10 mg group (HR 0.85, 95% CI 0.74–0.97; P = 0.019).
• Safety profiles were similar between the 5 mg and 10 mg groups.

Interpretation:

Further randomized dose-finding trials are warranted.

Limitations:

• The study was retrospective and based on claims data, which may limit the ability to establish causality.
• Only patients with both diabetes and heart failure were included due to reimbursement restrictions.

Conclusion:

5 mg daily SGLT2 inhibitors were associated with comparable risk to 10 mg in patients with diabetes and heart failure.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.